Key result
A mouse potency assay for Western equine encephalomyelitis vaccines yielded ED(50) rankings that were not different from those determined using guinea pigs.
A mouse potency assay for Western equine encephalomyelitis vaccines provides comparable vaccine rankings to the traditional guinea pig assay.
Mouse-based ED50 assay may simplify WEE vaccine potency testing; leaves open validation against guinea pig/hamster models.
A potency assay for Western equine encephalomyelitis vaccine was developed which utilized mice as the test animal instead of guinea pigs or hamsters. By immunizing several groups of mice with dilutions of the vaccine and challenging them intracerebrally with virulent virus, it was possible to determine mathematically a dose of vaccine capable of protecting 50% of the animals (ED(50)). When log dilutions of virulent virus were used to challenge mice which were immunized with dilutions of the vaccine, there was no difference among the ED(50) values for the dilutions of challenge virus. In a direct comparison of ED(50) values determined from the immunization of mice and those determined from the immunization of guinea pigs, there were no differences in the rankings of the vaccines.
No takes yet. Share an insight, caveat, or question.
Robinson et al. (1972) studied Western equine encephalomyelitis. Mouse potency assay vs. Guinea pig potency assay was evaluated on ED(50) (dose of vaccine capable of protecting 50% of the animals). A mouse potency assay for Western equine encephalomyelitis vaccines yielded ED(50) rankings that were not different from those determined using guinea pigs.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: